Rising Cancer Incidence, Advances in Immunotherapy, and Government Support Drive Growth in the Global Cancer Vaccine Market

Cancer vaccine market was valued at $11.20 billion in 2024 and is projected to reach $36.14 billion by 2035, growing at a CAGR of 11.3% during the forecast period (2025–2035). The global cancer vaccine market is gaining momentum as the incidence of cancer continues to rise worldwide, increasing the need for innovative preventive and therapeutic solutions. Growing awareness of early intervention and immunization-based approaches is encouraging healthcare systems to integrate cancer vaccines into broader oncology care strategies.

Browse the full report description of “Cancer Vaccine Market Size, Share & Trends Analysis Report by Type (Preventive Vaccines, and Therapeutic Vaccines) by Technology (Dendritic Cell Vaccines, Conjugate Vaccines, Inactivated Vaccines, Live Attenuated Vaccines, and Recombinant Vector Vaccines) and by End-User (Hospitals and Clinics, Research Institutes, Pharmaceuticals & Biotechnology Companies, and Others) Forecast Period (2025-2035)” of https://www.omrglobal.com/industry-reports/cancer-vaccine-market

At the same time, rapid advancements in immunotherapy—including personalized cancer vaccines, neoantigen-based platforms, and mRNA technologies—are transforming treatment paradigms. Supportive government initiatives, such as increased funding for cancer research, accelerated regulatory pathways, and public–private collaborations, are further strengthening market expansion.

Global Developments Highlight the Growing Importance of Cancer Vaccines

• 2024: Several governments increased funding for cancer immunotherapy programs, supporting clinical trials for therapeutic cancer vaccines targeting melanoma, lung, and colorectal cancers.
• 2024-2025: Biopharmaceutical companies expanded collaborations with academic research centers to advance personalized and mRNA-based cancer vaccine platforms.
• 2025: Regulatory agencies in key markets introduced fast-track and breakthrough designations for promising cancer vaccine candidates, accelerating development timelines and patient access.

Strategic Collaborations and R&D Intensification Shape Market Progress

Pharmaceutical and biotechnology companies are intensifying R&D efforts to develop next-generation cancer vaccines with improved efficacy and safety profiles. Strategic partnerships with research institutes, clinical centers, and government agencies are accelerating clinical trials, commercialization, and global market access.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
• Type
• Technology
• End-User

• Competitive Landscape – GlaxoSmithKline plc (GSK), Merck & Co. Inc., Moderna Inc., Pfizer Inc. and Sanofi S.A.

 Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

 Global Cancer Vaccine Market Report Segment

By Type

• Preventive Vaccines
• Therapeutic vaccines

By Technology

• Dendritic Cell Vaccines
• Conjugate Vaccines
• Inactivated Vaccines
• Live Attenuated Vaccines
• Recombinant Vector Vaccines

By End-User

• Hospitals and Clinics
• Research Institutes
• Pharmaceuticals & Biotechnology Companies
• Others

Global Cancer Vaccine Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

 Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

 To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/cancer-vaccine-market